Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates

Bonomi M, Nortilli R, Molino A, Sava T, Santo A, Caldara A, et al.. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. Med Oncol. 2009 Mar 28 [Epub ahead of print]. Dincer M, Altundag K, Harputluoglu H, Aksoy S, Cengiz M, Gullu I. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol. 2008;25:356–9. doi:10.1007/s12032-008-9045-3. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–36. doi:10.1359/jbmr.080205.